Table 2. Percentage (95% CI) of subjects with seroresponse 1 mo after MenACWY-CRM197 vaccination by pre-vaccination status, overall and by age group.
| Seroresponse (%) By age group |
|||||
|---|---|---|---|---|---|
|
Serogroup |
Sample size (N of children; adolescents; adults) |
Seroresponse (%) Overall (≥2 y) |
Children (2 to 10 y) |
Adolescents (11 to 17 y) |
Adults (≥18 y) |
| Men A | |||||
| Seronegative (hSBA < 1:4) | 176 (61; 60; 55) | 88 (82–92) | 89 (78–95) | 92 (82–97) | 84 (71–92) |
| Seropositive (hSBA ≥ 1:4) | 17 (2; 5; 10) | 53 (28–77) | 100 (16–100) | 60 (15–95) | 40 (12–74) |
| Overall | 193 (63; 65; 65) | 85 (79–90) | 89 (78–95) | 89 (79–96) | 77 (65–86) |
| Men C | |||||
| Seronegative (hSBA < 1:4) | 126 (51; 46; 29) | 77 (69–84) | 71 (56–83) | 83 (69–92) | 79 (60–92) |
| Seropositive (hSBA ≥ 1:4) | 66 (11; 19; 36) | 68 (56–79) | 64 (31–89) | 79 (54–94) | 64 (46–79) |
| Overall | 192 (62; 65; 65) | 74 (67–80) | 69 (56–80) | 82 (70–90) | 71 (58–81) |
| Men W | |||||
| Seronegative (hSBA < 1:4) | 80 (42; 19; 19) | 93 (84–97) | 93 (81–99) | 95 (74–100) | 89 (67–99) |
| Seropositive (hSBA ≥ 1:4) | 112 (20; 46; 46) | 37 (28–46) | 30 (12–54) | 33 (20–48) | 43 (29–59) |
| Overall | 192 (62; 65; 65) | 60 (53–67) | 73 (60–83) | 51 (38–63) | 57 (44–69) |
| Men Y | |||||
| Seronegative (hSBA < 1:4) | 151 (54; 49; 48) | 87 (80–92) | 78 (64–88) | 96 (86–100) | 88 (75–95) |
| Seropositive (hSBA ≥ 1:4) | 40 (7; 16; 17) | 70 (53–83) | 71 (29–96) | 63 (35–85) | 76 (50–93) |
| Overall | 191 (61; 65; 65) | 83 (77–88) | 77 (65–87) | 88 (77–95) | 85 (74–92) |
Seroresponse was defined as the percentage of subjects with post-vaccination hSBA ≥ 1:8 in subjects with a pre-vaccination hSBA < 1:4, and at least a 4-fold increase in post-vaccination hSBA in subjects with pre-vaccination hSBA ≥ 1:4.